Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 01 September, 2005

XTL Biopharm Ltd

ADR's to trade on NASDAQ

XTL Biopharmaceuticals Ltd
1 September 2005

XTLbio ADRs to Commence Trading on US NASDAQ National Market

Rehovot, Israel, 1 September 2005: XTL Biopharmaceuticals Ltd. (LSE: XTL)
(XTLbio) announced that it has completed the registration process for its shares
with the US Securities and Exchange Commission and that its shares are scheduled
to begin trading today Thursday 1 September 2005 on the US NASDAQ National
Market under the ticker symbol 'XTLB'. Trading will be in the form of American
Depository Receipts ('ADRs)', each ADR representing ten (10) ordinary shares.
Depository bank for the ADR program is the Bank of New York.
Michael S. Weiss, Chairman of XTLbio, commented: 'We are very pleased to join
the ranks of the leading biotechnology companies that are traded on the NASDAQ.
We believe that this is a major milestone for the Company and will help us
attract US investors and analysts.'


Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. Established in 1993, XTLbio became a public company in
2000 and its ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange under the symbol XTL, on
the Tel Aviv Stock Exchange, Israel and on NASDAQ under the symbol XTLB.

Cautionary Statement
Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the U.S. Private Securities Litigation Reform Act of
1995. Among the factors that could cause our actual results to differ
materially, and therefore affect interest by investors in our ADR's, are the
following: our ability to successfully complete cost-effective clinical trials
for the drug candidates in our pipelines and other risk factors identified from
time to time in our reports filed with the regulatory authorities in Israel, the
United Kingdom and the United States. Any forward-looking statements set forth
in this press release speak only as of the date of this press release. We do not
intend to update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at The information in our website is not
incorporated by reference into this press release and is included as an inactive
textual reference only.

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t